Executive SummaryWest German firm Schering AG agrees to acquire all the outstanding common stock of the closely held, California-based biotechnology firm. The two companies have previously collaborated in the cardiovascular area. "Codon's development of anticoagulant proteins is especially promising," Schering AG said.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.